Real‐world practitioner perceptions of CARTITUDE‐4 results for patients with previously treated multiple myeloma
Abstract Introduction Initially approved for the fifth‐line or later therapeutic setting, the chimeric antigen receptor (CAR) T‐cell regimen ciltacabtagene autoleucel (cilta‐cel) was recently approved for second‐line (2L) treatment in relapsed/refractory multiple myeloma (RRMM). Oncology practitione...
Saved in:
| Main Authors: | Alexandrina Balanean, Samuel Baird, Brooke Dulka, Luke Jennings‐Zhang, Robert N. Bone, Yolaine Jeune‐Smith, Bruce Feinberg, Muhamed Baljevic |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.1047 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical Insights on Brexucabtagene Autoleucel for the Treatment of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
by: Kopmar NE, et al.
Published: (2024-11-01) -
Targeting BCMA in multiple myeloma: designs, challenges, and future directions
by: Yi Hu, et al.
Published: (2025-02-01) -
Redefining the role of Learning Development practitioners
by: Steve Briggs
Published: (2025-01-01) -
Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma
by: Jianmin Guo, et al.
Published: (2024-11-01) -
Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia
by: P. Joy Ho, et al.
Published: (2025-01-01)